These parameters not only determine which form of systemic therapy (i.e., chemo-/endocrine-/targeted therapy) should be prescribed but sometimes also predict therapeutic responsiveness (endocrine therapy for ER- or PR-positive and anti-HER2 targeted therapy for HER2-positive breast cancer). Here, PGR is linked to breast carcinoma.